These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 19167420

  • 1. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor.
    Kakui N, Yokoyama F, Yamauchi M, Kitamura K, Imanishi T, Inoue T, Koyama T.
    Pharmacol Biochem Behav; 2009 May; 92(3):393-8. PubMed ID: 19167420
    [Abstract] [Full Text] [Related]

  • 2. Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors.
    Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M.
    J Physiol Pharmacol; 2002 Mar; 53(1):105-16. PubMed ID: 11939713
    [Abstract] [Full Text] [Related]

  • 3. Anxiolytic effects of yokukansan, a traditional Japanese medicine, via serotonin 5-HT1A receptors on anxiety-related behaviors in rats experienced aversive stress.
    Yamaguchi T, Tsujimatsu A, Kumamoto H, Izumi T, Ohmura Y, Yoshida T, Yoshioka M.
    J Ethnopharmacol; 2012 Sep 28; 143(2):533-9. PubMed ID: 22819689
    [Abstract] [Full Text] [Related]

  • 4. Mirtazapine exerts an anxiolytic-like effect through activation of the median raphe nucleus-dorsal hippocampal 5-HT pathway in contextual fear conditioning in rats.
    An Y, Chen C, Inoue T, Nakagawa S, Kitaichi Y, Wang C, Izumi T, Kusumi I.
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct 03; 70():17-23. PubMed ID: 27137833
    [Abstract] [Full Text] [Related]

  • 5. Anxiolytic-like effect of mirtazapine mediates its effect in the median raphe nucleus.
    An Y, Inoue T, Kitaichi Y, Izumi T, Nakagawa S, Song N, Chen C, Li X, Koyama T, Kusumi I.
    Eur J Pharmacol; 2013 Nov 15; 720(1-3):192-7. PubMed ID: 24436979
    [Abstract] [Full Text] [Related]

  • 6. Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan.
    de Boer TH, Nefkens F, van Helvoirt A, van Delft AM.
    J Pharmacol Exp Ther; 1996 May 15; 277(2):852-60. PubMed ID: 8627567
    [Abstract] [Full Text] [Related]

  • 7. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.
    Nakayama K, Sakurai T, Katsu H.
    Brain Res Bull; 2004 Apr 30; 63(3):237-41. PubMed ID: 15145142
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The pharmacologic profile of mirtazapine.
    de Boer T.
    J Clin Psychiatry; 1996 Apr 30; 57 Suppl 4():19-25. PubMed ID: 8636062
    [Abstract] [Full Text] [Related]

  • 10. Tolerability and safety aspects of mirtazapine.
    Nutt DJ.
    Hum Psychopharmacol; 2002 Jun 30; 17 Suppl 1():S37-41. PubMed ID: 12404669
    [Abstract] [Full Text] [Related]

  • 11. Subchronic lithium treatment increases the anxiolytic-like effect of mirtazapine on the expression of contextual conditioned fear.
    An Y, Inoue T, Kitaichi Y, Nakagawa S, Wang C, Chen C, Song N, Kusumi I.
    Eur J Pharmacol; 2015 Jan 15; 747():13-7. PubMed ID: 25438255
    [Abstract] [Full Text] [Related]

  • 12. Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions.
    Yamamura S, Abe M, Nakagawa M, Ochi S, Ueno S, Okada M.
    Neuropharmacology; 2011 Mar 15; 60(4):550-60. PubMed ID: 21195096
    [Abstract] [Full Text] [Related]

  • 13. 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala.
    Li X, Inoue T, Abekawa T, Weng S, Nakagawa S, Izumi T, Koyama T.
    Eur J Pharmacol; 2006 Feb 17; 532(1-2):74-80. PubMed ID: 16460727
    [Abstract] [Full Text] [Related]

  • 14. Effects of the 5-HT2A antagonist mirtazapine in rat models of thermoregulation.
    Pawlyk AC, Cosmi S, Alfinito PD, Maswood N, Deecher DC.
    Brain Res; 2006 Dec 06; 1123(1):135-44. PubMed ID: 17067560
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of mirtazapine in clinically relevant subgroups of depressed patients.
    Nutt DJ.
    Depress Anxiety; 1998 Dec 06; 7 Suppl 1():7-10. PubMed ID: 9597345
    [Abstract] [Full Text] [Related]

  • 16. Involvement of dopamine D1 receptors and alpha1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test.
    Hirano S, Miyata S, Onodera K, Kamei J.
    Eur J Pharmacol; 2007 May 07; 562(1-2):72-6. PubMed ID: 17328889
    [Abstract] [Full Text] [Related]

  • 17. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear.
    Nishikawa H, Inoue T, Masui T, Izumi T, Koyama T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May 09; 31(4):926-31. PubMed ID: 17376576
    [Abstract] [Full Text] [Related]

  • 18. Bidirectional modulation of classical fear conditioning in mice by 5-HT(1A) receptor ligands with contrasting intrinsic activities.
    Youn J, Misane I, Eriksson TM, Millan MJ, Ogren SO, Verhage M, Stiedl O.
    Neuropharmacology; 2009 May 09; 57(5-6):567-76. PubMed ID: 19607850
    [Abstract] [Full Text] [Related]

  • 19. 5-HT-1A receptor responsiveness following subchronic administration of buspirone.
    Khan A, Haleem DJ.
    Pak J Pharm Sci; 2006 Oct 09; 19(4):333-7. PubMed ID: 17105715
    [Abstract] [Full Text] [Related]

  • 20. The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
    Stachowicz K, Kłodzińska A, Palucha-Poniewiera A, Schann S, Neuville P, Pilc A.
    Neuropharmacology; 2009 Sep 09; 57(3):227-34. PubMed ID: 19539634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.